Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04255160 · ClinicalTrials.gov registry record · Phase 4
Impact of Estradiol on Endothelial Function in Peri-Menopausal Women
A Phase 4 study of Vasodilation and Perimenopause, sponsored by University of Delaware.
- Active
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04255160: Active Phase 4 study of Vasodilation and Perimenopause, sponsored by University of Delaware.
NCT04255160 is a Phase 4 study of Vasodilation and Perimenopause that is active but no longer recruiting, run by University of Delaware. The registered enrollment target is 80 participants, above the 64-participant average among 8 other Vasodilation trials with a reported enrollment target (25% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04255160, a Phase 4 study of Vasodilation and Perimenopause, is active but no longer recruiting, sponsored by University of Delaware.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify the impact of estradiol (E2) on the mechanisms that regulate vascular endothelial function in peri-menopausal (PERI) women. This study is the first step in understanding factors contributing to endothelial dysfunction in women with advancing reproductive age and in response to E2 administration.
Primary Outcome
The capacity of the large and small blood vessels to dilate.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Estradiol (mylan or vivelle dot patch)
Study Locations (1)
Delaware
- University of Delaware - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 4 |
What the registry record for NCT04255160 still lists
NCT04255160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 64-participant average among 8 other Vasodilation trials with a reported enrollment target (25% higher).
The record links to 3 conditions, with Vasodilation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04255160 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT04255160 about?
NCT04255160 is a clinical study titled "Impact of Estradiol on Endothelial Function in Peri-Menopausal Women". The purpose of this study is to identify the impact of estradiol (E2) on the mechanisms that regulate vascular endothelial function in peri-menopausal (PERI) women. This study is the first step in understanding factors contributing to endothelial dysfunction in women with advancing reproductive age ...
What is the current status of trial NCT04255160?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2020-10-01. Estimated completion is 2026-06-30.
What conditions does trial NCT04255160 study?
This clinical trial studies the following conditions: Vasodilation, Perimenopause, Estrogen.
What interventions are being tested in trial NCT04255160?
The interventions under investigation include: Placebo (OTHER), Estradiol (mylan or vivelle dot patch) (DRUG).
Who is sponsoring clinical trial NCT04255160?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04255160 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vasodilation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04255160's enrollment target sits among peer trials
80 3rd of 8 higher than 6 of 8 other Vasodilation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vasodilation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Red Light Treatment in Peripheral Artery Disease
RECRUITING · NA
-
Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
RECRUITING · Early Phase 1
-
Vasodilator and Exercise Study for DMD (VASO-REx)
RECRUITING · Phase 2
-
Reducing Blood Pressure in Mid-life Adult Binge Drinkers
RECRUITING · NA
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Sympatholysis and Impact of Obesity
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI